No Detail Found!

HIPEC in Ovarian Cancer: When and to Whom?

Author(s)
Ozturk Ates Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Bulent Aksel Department of General Surgery, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Mehmet Hadi Akkus Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Irem Oner Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Cemil Yuksel Department of General Surgery, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Mutlu Dogan Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,Ankara,Turkey
Abstract
Objective: To evaluate the optimal candidates for hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer. Study Design: Descriptive study. Place and Duration of the Study:Health Sciences University, Dr. Abdurrahman YurtasianAnkara Oncology Training and Research Hospital, Ankara, Turkey, between 2013 and 2021. Methodology: Ovarian cancer patients who underwent HIPEC and CRS for peritoneal involvement were included in this study. Thermosolutions were prepared as a closed system by using HT 2000 hyperthermic perfusion device. Then, cisplatin was applied at 100 mg/m2 at 42-42.5 °C for 60 minutes after CRS. Results: A total of 47 patients were enrolled. The median age was 54 years (27-80) at the time of diagnosis. Forty (85.1%) patients had high grade serous carcinoma and 22 (46.7%) patients had clinical stage 3C disease. The median peritoneal cancer index (PCI) was 13 (3-24) in the whole population. HIPEC was applied as rst-line treatment in 25 (51%) patients. Eleven (23.4%) patients had HIPEC in the post-neoadjuvant interval whereas 10 (21.3%) patients had it in platinum sensitive relapse. Median progression free survival (PFS) was 31(95% CI:11-50), 33 (95% CI:1-67), and 18 (95% CI:8-27) months in the primary, post-neoadjuvant interval, and platinum-sensitive relapse HIPEC groups, respectively. The patients with lower PCI (PCI13, 145 months versus 42 months, p=0.034). Conclusion: HIPEC with CRS should be considered in selected serous carcinoma patients with peritoneal involvement, especially for the patients with primary ovarian cancer with lower PCI (PCI<13).
Publication Details
Page(s) 1001-1005
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 9, Year: 2023

Request the full text from PASTIC

Keywords
Ovarian cancer, HIPEC, Peritoneal cancer index
0

Citations

0

Downloads

67

Views